Evidence map›Paper›PMID 36254612›Full record

ArticleClinical chemistry2023

The Inflammation Biomarker GlycA Reflects Plasma N-Glycan Branching.

Maxence Noel, Daniel I Chasman, Samia Mora, James D Otvos, Christopher D Palmer, Patrick J Parsons, Jordan W Smoller, Richard D Cummings, Robert G Mealer

Open access · bronzeAbstract read
In one paragraph

Article in Clinical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. The Role of Clinical Glyco(proteo)mics in Precision Medicine.Molecular & cellular proteomics : MCP · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Maxence NoelDepartment of Surgery, National Center for Functional Glycomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Daniel I ChasmanPreventive Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3357-0862
Samia MoraPreventive Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6283-0980
James D OtvosLaboratory Corporation of America Holdings, Morrisville, NC, USA.
Christopher D PalmerNew York State Department of Health, Laboratory of Inorganic and Nuclear Chemistry, Wadsworth Center, Albany, NY, USA.
Patrick J ParsonsNew York State Department of Health, Laboratory of Inorganic and Nuclear Chemistry, Wadsworth Center, Albany, NY, USA.
Jordan W SmollerThe Stanley Center for Psychiatric Research at Broad Institute of Harvard/MIT, Cambridge, MA, USA.
Richard D CummingsDepartment of Surgery, National Center for Functional Glycomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8918-5034
Robert G MealerDepartment of Surgery, National Center for Functional Glycomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5963-2836
Beth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USBroad Institute · USNew York State Department of Health · USLabCorp (United States) · US

Funding

Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
Protein-Glycan Interaction Resource at the National Center for Functional Glycomics (NCFG)R24GM137763 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI RICHARD D CUMMINGS · 2020 to 2026
$5.8M
Whole Genome Sequencing to support GenomeTrakr-Discipline A: Microbiology- Track 4U19FD007089 · FDA · WADSWORTH CENTER · PI EGAN, CHRISTINA, PARSONS, PATRICK J. · 2020 to 2024
$4.5M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
Glycoproteomics and the Glycosylation Code of the Brain in Asymptomatic and Symptomatic Alzheimer’s DiseaseRF1AG062181 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CUMMINGS, RICHARD D, SEYFRIED, NICHOLAS THOMAS · 2018 to 2018
$4.1M
The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upUM1CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2014 to 2018
$4.0M
Total plasma and IgG glycomes, statin therapy and ASCVD eventsR01HL117861 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2013 to 2022
$3.8M
Targeting the Active Resolution of Inflammation for Cardiovascular Disease PreventionR01HL160799 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2022 to 2025
$3.0M
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid PathwaysR01HL134811 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2017 to 2020
$3.0M
Translational Neuroscience Training for CliniciansT32MH112485 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI BUCKNER, RANDY L, ROFFMAN, JOSHUA LAWRENCE · 2018 to 2022
$1.7M
TRIAL OF VITAMIN E, BETA-CAROTENE &ASPRIN IN WOMENR01HL043851 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1991 to 2000
$1.6M
Patient Centered Approaches to Preventing ASCVD EventsK24HL136852 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SAMIA MORA · 2018 to 2026
$1.1M
FDA HHS U19 FD007089NCEH CDC HHS UE2 EH001329NCI NIH HHS CA047988 and UM1CA182913NCI NIH HHS R01 CA047988NCI NIH HHS UM1 CA182913NHLBI NIH HHS HL043851 and HL080467, HL099355NHLBI NIH HHS K24 HL136852NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS R01 HL117861NHLBI NIH HHS R01 HL134811NHLBI NIH HHS R01 HL160799NHLBI NIH HHS RC1 HL099355NIA NIH HHS RF1 AG062181NIGMS NIH HHS R24 GM137763NIH HHS RF1AG062181NIMH NIH HHS K08 MH128712NIMH NIH HHS T32 MH112485
6 · The paper itself

Abstract

backgroundGlycA is a nuclear magnetic resonance (NMR) signal in plasma that correlates with inflammation and cardiovascular outcomes in large data sets. The signal is thought to originate from N-acetylglucosamine (GlcNAc) residues of branched plasma N-glycans, though direct experimental evidence is limited. Trace element concentrations affect plasma glycosylation patterns and may thereby also influence GlycA.

methodsNMR GlycA signal was measured in plasma samples from 87 individuals and correlated with MALDI-MS N-glycomics and trace element analysis. We further evaluated the genetic association with GlycA at rs13107325, a single nucleotide polymorphism resulting in a missense variant within SLC39A8, a manganese transporter that influences N-glycan branching, both in our samples and existing genome-wide association studies data from 22 835 participants in the Women's Health Study (WHS).

resultsGlycA signal was correlated with both N-glycan branching (r2 ranging from 0.125-0.265; all P < 0.001) and copper concentration (r2 = 0.348, P < 0.0001). In addition, GlycA levels were associated with rs13107325 genotype in the WHS (β [standard error of the mean] = -4.66 [1.2674], P = 0.0002).

conclusionsThese results provide the first direct experimental evidence linking the GlycA NMR signal to N-glycan branching commonly associated with acute phase reactive proteins involved in inflammation.

Indexed as

InflammationAcetylglucosamineAcute-Phase ProteinsBiomarkersCation Transport ProteinsFemaleGenome-Wide Association StudyHumansPolysaccharidesTrace ElementsAcetylglucosamineAcute-Phase ProteinsBiomarkersCation Transport ProteinsPolysaccharidesSLC39A8 protein, humanTrace Elements

Identifiers

PMID36254612
PMCPMC10726709
OpenAlexW4306679635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.